{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:10:02Z","timestamp":1784031002043,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epithelioid hemangioendothelioma (EHE) represents an extremely uncommon vascular sarcoma subentity. The clinical characteristics vary from low grade localized to high grade systemic disease and treatment ranges from active surveillance versus intensive therapeutic strategies. Due to its rarity, a standardized clinical management including an appropriate therapeutic approach has not yet been defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with EHE presenting at the Charit\u00e9-Universit\u00e4tsmedizin Berlin between 1997 and 2022 were included in the analysis. A retrospective database was established comprising demographic specifications, treatment, pathological features (including TFE3 expression level) and prognosis. Our single-centre data was then compared to previously published cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941 patients, with\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916 men (39%) and\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925 women (61%) with a median age of 53 years (range 20\u201388). The patients had limited comorbidities (median Charlson Comorbidity Index, CCI: 3) and a good performance status (median ECOG: 1). Median overall survival was not reached, with only\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093 patients (7%) showing an aggressive course of disease (progression-free survival (PFS)\u2009\u2264\u200928 days). Isolated liver involvement was the predominant clinical presentation, observed in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926 patients (63%). At initial diagnosis,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917 (41%) patients showed systemic symptoms (e.g. anemia, weight loss) and\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912 (29%) already had metastatic disease. Surgery was performed for therapeutic and\/or diagnostic purposes in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920 (49%) patients, whereas only\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095 (12%) received chemotherapy. In\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092 of the latter, disease stabilization was achieved. Liver transplantation was performed in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095 (12%) patients and was associated with persisting disease-free survival. Molecular genetic data was retrieved in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921 (51%) patients regarding WWTR1-CAMTA1 fusion, and in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918 (44%) patients regarding TFE3 positivity. In 67% of analyzed samples, CAMTA1 fusion was found. In contrast, TFE3 expression was observed in 22% only. Both CAMTA1 fusion and TFE3 positivity were observed in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093 patients (18%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis of EHE patients treated at Charit\u00e9-Universit\u00e4tsmedizin Berlin mirrors published cohorts regarding clinical behavior and OS. The observed clinical heterogeneity underlines the necessity for personalized therapeutic strategies in this rare disease. Molecular characterization is increasingly recognized as a component of contemporary clinical care, as it may identify molecular subclasses associated with aggressive disease and guide management strategies in the future. Moreover, standardized molecular profiling also enables evaluation of patient eligibility for clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06549-y","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:04:48Z","timestamp":1783746288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of patients with epithelioid hemangioendothelioma (EHE): a retrospective analysis of the Charit\u00e9- Universit\u00e4tsmedizin Berlin"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0612-3023","authenticated-orcid":false,"given":"Jana K.","family":"Striefler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Str\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmiester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. E. Heil","family":"Olaizola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Benckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ihlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jarosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"von Laffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Roohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"\u00d6llinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wittenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"M\u00e4rdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fl\u00f6rcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"6549_CR1","doi-asserted-by":"publisher","unstructured":"Antonescu CR et al (2013) Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosom Cancer 52(8):775\u2013784 https:\/\/doi.org\/10.1002\/gcc.22073","DOI":"10.1002\/gcc.22073"},{"key":"6549_CR2","doi-asserted-by":"publisher","unstructured":"Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M (2003) Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 27(6):750\u2013761 https:\/\/doi.org\/10.1097\/00000478-200306000-00005","DOI":"10.1097\/00000478-200306000-00005"},{"key":"6549_CR3","doi-asserted-by":"publisher","unstructured":"Cardinal J et al. (2009) Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. Arch Surg Chic Ill (1960) 144(11):1035\u20131039 https:\/\/doi.org\/10.1001\/archsurg.2009.121","DOI":"10.1001\/archsurg.2009.121"},{"key":"6549_CR4","doi-asserted-by":"publisher","unstructured":"Deyrup AT, Tighiouart M, Montag AG, Weiss SW (2008) Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol 32(6):924\u2013927. https:\/\/doi.org\/10.1097\/pas.0b013e31815bf8e6","DOI":"10.1097\/pas.0b013e31815bf8e6"},{"key":"6549_CR5","doi-asserted-by":"publisher","unstructured":"Errani C et al (2011) A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosom Cancer 50(8):644\u2013653 https:\/\/doi.org\/10.1002\/gcc.20886","DOI":"10.1002\/gcc.20886"},{"key":"6549_CR6","unstructured":"Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2022) WHO classification of tumours of soft tissue and bone. [Online]. Available: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/WHO-Classification-Of-Tumours-Of-Soft-Tissue-And-Bone-2013. Accessed 24 July 2022"},{"key":"6549_CR7","doi-asserted-by":"publisher","unstructured":"Frezza AM et al (2021) Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med 10(8):2645\u20132659 https:\/\/doi.org\/10.1002\/cam4.3807","DOI":"10.1002\/cam4.3807"},{"key":"6549_CR8","doi-asserted-by":"publisher","unstructured":"Frezza AM et al (2024) The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: the protocol of an international and collaborative effort on an ultra-rare entity. PLOS ONE 19(8):e0308387 https:\/\/doi.org\/10.1371\/journal.pone.0308387","DOI":"10.1371\/journal.pone.0308387"},{"key":"6549_CR9","doi-asserted-by":"publisher","unstructured":"Habeeb O, Rubin BP (2019) The molecular diagnostics of vascular neoplasms. Surg Pathol Clin 12(1):35\u201349 https:\/\/doi.org\/10.1016\/j.path.2018.10.002","DOI":"10.1016\/j.path.2018.10.002"},{"key":"6549_CR10","doi-asserted-by":"publisher","unstructured":"H\u00f8yer M et al (2012) Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 82(3):1047\u20131057. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.07.020","DOI":"10.1016\/j.ijrobp.2011.07.020"},{"key":"6549_CR11","doi-asserted-by":"publisher","unstructured":"Kamarajah SK, Robinson D, Littler P, White SA (2018) Small, incidental hepatic epithelioid haemangioendothelioma the role of ablative therapy in borderline patients. J Surg Case Rep 2018:rjy223. https:\/\/doi.org\/10.1093\/jscr\/rjy223","DOI":"10.1093\/jscr\/rjy223"},{"key":"6549_CR12","doi-asserted-by":"publisher","unstructured":"Kitaichi M et al (1998) Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J 12(1):89\u201396 https:\/\/doi.org\/10.1183\/09031936.98.12010089","DOI":"10.1183\/09031936.98.12010089"},{"key":"6549_CR13","doi-asserted-by":"publisher","unstructured":"Kou K et al (2020) Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy. World J Clin Cases 8(18):3978\u20133987. https:\/\/doi.org\/10.12998\/wjcc.v8.i18.3978","DOI":"10.12998\/wjcc.v8.i18.3978"},{"key":"6549_CR14","doi-asserted-by":"publisher","unstructured":"Lau K et al (2011) Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 140(5):1312\u20131318 https:\/\/doi.org\/10.1378\/chest.11-0039","DOI":"10.1378\/chest.11-0039"},{"key":"6549_CR15","doi-asserted-by":"publisher","unstructured":"Lee SJ, Yang WI, Chung W-S, Kim SK (2016) Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements. Oncotarget 7(7):7480\u20137488. https:\/\/doi.org\/10.18632\/oncotarget.7060","DOI":"10.18632\/oncotarget.7060"},{"key":"6549_CR16","doi-asserted-by":"publisher","first-page":"2349991","DOI":"10.1155\/2022\/2349991","volume":"2022","author":"Z Liu","year":"2022","unstructured":"Liu Z, He S (2022) Epithelioid hemangioendothelioma: incidence, mortality, prognostic factors, and survival analysis using the surveillance, epidemiology, and end results database. J Oncol 2022:2349991. https:\/\/doi.org\/10.1155\/2022\/2349991","journal-title":"J Oncol"},{"key":"6549_CR17","doi-asserted-by":"publisher","unstructured":"Mehrabi A et al (2006) Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 107(9):2108\u20132121 https:\/\/doi.org\/10.1002\/cncr.22225","DOI":"10.1002\/cncr.22225"},{"key":"6549_CR18","doi-asserted-by":"publisher","unstructured":"Pobbati AV, Kumar R, Rubin BP, Hong W (2023) Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem Sci 48(5):450\u2013462. https:\/\/doi.org\/10.1016\/j.tibs.2022.12.005","DOI":"10.1016\/j.tibs.2022.12.005"},{"key":"6549_CR19","doi-asserted-by":"publisher","unstructured":"Rao Q et al (2013) TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol 37(6):804\u2013815. https:\/\/doi.org\/10.1097\/PAS.0b013e31827e17cb","DOI":"10.1097\/PAS.0b013e31827e17cb"},{"key":"6549_CR20","doi-asserted-by":"publisher","unstructured":"Ritschl PV et al (2020) The effects of MELD-based liver allocation on patient survival and waiting list mortality in a country with a low donation rate. J Clin Med 9(6):1929. https:\/\/doi.org\/10.3390\/jcm9061929","DOI":"10.3390\/jcm9061929"},{"key":"6549_CR21","doi-asserted-by":"publisher","unstructured":"Rosenberg A, Agulnik M (2018) Epithelioid hemangioendothelioma: update on diagnosis and treatment. Curr Treat Options Oncol 19(4):19. https:\/\/doi.org\/10.1007\/s11864-018-0536-y","DOI":"10.1007\/s11864-018-0536-y"},{"key":"6549_CR22","doi-asserted-by":"publisher","unstructured":"Sardaro A, Bardoscia L, Petruzzelli MF, Portaluri M (2014) Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev 8(2):259. https:\/\/doi.org\/10.4081\/oncol.2014.259","DOI":"10.4081\/oncol.2014.259"},{"key":"6549_CR23","doi-asserted-by":"publisher","unstructured":"Schuetze S et al (2021) P10015\/SARC033: a phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE). J Clin Oncol 39(15_suppl):11503\u201311503 https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.11503","DOI":"10.1200\/JCO.2021.39.15_suppl.11503"},{"key":"6549_CR24","doi-asserted-by":"publisher","unstructured":"Sharain RF, Gown AM, Greipp PT, Folpe AL (2019) Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Hum Pathol 87:65\u201374. https:\/\/doi.org\/10.1016\/j.humpath.2019.02.008","DOI":"10.1016\/j.humpath.2019.02.008"},{"key":"6549_CR25","doi-asserted-by":"publisher","unstructured":"Stacchiotti S et al (2021) Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100170","DOI":"10.1016\/j.esmoop.2021.100170"},{"key":"6549_CR26","doi-asserted-by":"publisher","unstructured":"Stacchiotti S, Tap W, Leonard H, Zaffaroni N, Baldi GG (2023) New molecular insights, and the role of systemic therapies and collaboration for treatment of epithelioid hemangioendothelioma (EHE). Curr Treat Options Oncol 24(6):667\u2013679 https:\/\/doi.org\/10.1007\/s11864-023-01076-1","DOI":"10.1007\/s11864-023-01076-1"},{"key":"6549_CR27","doi-asserted-by":"publisher","unstructured":"Suto H (2024) Role of the Hippo-YAP\/TAZ pathway in epithelioid hemangioendothelioma and its potential as a therapeutic target. Anticancer Res. 44(10):4147\u20134153 https:\/\/doi.org\/10.21873\/anticanres.17245","DOI":"10.21873\/anticanres.17245"},{"key":"6549_CR28","doi-asserted-by":"publisher","unstructured":"Tanas MR et al (2016) Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene 35(7):929\u2013938. https:\/\/doi.org\/10.1038\/onc.2015.148","DOI":"10.1038\/onc.2015.148"},{"key":"6549_CR29","doi-asserted-by":"publisher","unstructured":"Tomassen T et al (2023) Prognostic factors in epithelioid hemangioendothelioma: analysis of a nationwide molecularly\/immunohistochemically confirmed cohort of 57 cases. Cancers 15(13):3304. https:\/\/doi.org\/10.3390\/cancers15133304","DOI":"10.3390\/cancers15133304"},{"key":"6549_CR30","doi-asserted-by":"publisher","unstructured":"Treska V, Daum O, Svajdler M, Liska V, Ferda J, Baxa J (2017) Hepatic epithelioid hemangioendothelioma - a rare tumor and diagnostic dilemma. Vivo Athens Greece 31(4):763\u2013767. https:\/\/doi.org\/10.21873\/invivo.11128","DOI":"10.21873\/invivo.11128"},{"key":"6549_CR31","doi-asserted-by":"publisher","unstructured":"Tretiakova MS (2022) Chameleon TFE3-translocation RCC and how gene partners can change morphology: accurate diagnosis using contemporary modalities. Adv Anat Pathol 29(3):131\u2013140. https:\/\/doi.org\/10.1097\/PAP.0000000000000332","DOI":"10.1097\/PAP.0000000000000332"},{"key":"6549_CR32","doi-asserted-by":"publisher","unstructured":"Weiss SW, Enzinger FM (1982) Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 50(5):970\u2013981. https:\/\/doi.org\/10.1002\/1097-0142(19820901)50:5%3C970::aid-cncr2820500527%3E3.0.co;2-z","DOI":"10.1002\/1097-0142(19820901)50:5%3C970::aid-cncr2820500527%3E3.0.co;2-z"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06549-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06549-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06549-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:01:55Z","timestamp":1784030515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06549-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6549"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06549-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study involving human subjects has been performed with institutional ethical review board approval of Charit\u00e9 Ethics Committee (Approval Number EA2\/240\/20) and appropriate participants' written informed consent in compliance with the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"137"}}